Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...

Bristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed bag of new hires, sideways moves, and departures. The headline news is that ...